GermanyGermany

Cartilage network across European borders

17.02.2012

Brussels – European cartilage researchers intensify their cooperation. The 'gristle network' comprises scientists from Belgium, France, Germany and Luxembourg. Its members plan to meet regularly to exchange views and information about arthritis. "All members will benefit from the direct exchange and the intense cooperation in the network", Hening Madry, professor for experimental orthopaedics and arthrosis research at the university of the Saarland in Homburg, Germany. "For instance, we can talk about problems with cartilage repair or tissue cultivation."Besides Madry's university, the network members come from the Université Henri Poincaré in Nancy, the Fraunhofer IBMT in St.Ingbert, University of Liège, as well as the Centre de Recherche Public Henri Tudor and the university in Luxembourg.

GermanyGermany

05.08.2011

Boehringer Ingelheim is the first around the post. The European Commission cleared the German company's oral anticoagulant Pradaxa (dabigatran etexilate) for preventing stroke in atrial fibrillation patients at risk of stroke....

GermanyGermany

27.07.2011

Berlin – Reprogramming fibroblasts into human induced pluripotent stem cells (hiPSCs) can cause mitochondrial diseases, according to two reseearch groups from Berlin-based Max Planck Institute for Molecular Genetics. In every...

Germany, UKGermany

21.07.2011

In a first for European drug research, scientists have launched a clinical trial of an anti-HIV biotech medicine produced using genetically modified tobacco. Transgenic tobacco plants are grown for 45 days before being processed...

Germany, SwitzerlandGermany

19.07.2011

Basel - Roche goes shopping in Germany. The Swiss pharmaceutical giant agreed to buy privately-held mtm laboratories, a specialist in diagnostics for detecting cervical cancer based in Heidelberg, for up to 190 million...

GermanyGermany

08.07.2011

German pharmaceutical major Merck Serono has appointed Annalisa Jenkins as global head of drug development. The former head of Bristol-Myers Squibb’s global medical group is to lead her employer's drug development operations from...

GermanyGermany

08.07.2011

German pharmaceutical major Merck Serono has appointed Annalisa Jenkins as global head of drug development. The former head of Bristol-Myers Squibb’s global medical group is to lead her employer's drug development operations from...

Displaying results 31 to 40 out of 454

< Previous 31-40 Next >

© 2007-2015 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/3/article/cartilage-network-across-european-borders.html

Video

All videos

Product of the week

Products

WhitePaper

LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Events

All Events

Partner-Events

München

BioVaria 2015

Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...

Stock list

All quotes

TOP

  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%

FLOP

  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%

TOP

  • 4SC1.30 EUR54.8%
  • WILEX3.59 EUR22.9%
  • CO.DON3.15 EUR19.3%

FLOP

  • MOLOGEN5.08 EUR-35.6%
  • CYTOS1.01 CHF-34.4%
  • BIOTEST79.20 EUR-22.5%

TOP

  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%

FLOP

  • MOLOGEN5.08 EUR-54.7%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 24.04.2015

Current issue

All issues